3D phenotyping in a Colombian population reveals unique population and ontogenic facial patterns in genetic and rare disorders

Mireia Andreu-Montoriol[1*], Marina Pujol[1*], Luis Miguel Echeverry-Quiceno[1], Estephania Candelo[2,3], Álvaro Heredia-Lidón[4], Eidith Gómez[2], Ona Roure-Ramis[1], Max Rubert-Tayà[1], Xavier Sevillano[4], Maria Esther Esteban[1,5], Aroa Casado[1], Harry Pachajoa[2,3] and Neus Martínez-Abadías[1]

[1] Departament de Biologia Evolutiva, Ecologia i Ciències Ambientals (BEECA), Facultat de Biologia, Universitat de Barcelona (UB), Barcelona, 08028, Spain

[2] Centro de Investigaciones en Anomalías Congénitas y Enfermedades Raras (CIACER), Universidad Icesi, Cali, Colombia.

[3] Servicio de Genética Clínica, Fundación Valle del Lili, Cali, Colombia.

[4] Human-Environment Research Group, La Salle - Universitat Ramon Llull, Barcelona, 08022, Spain.

[5] Institut de Recerca de la Biodiversitat (IRBio), Universitat de Barcelona, Barcelona, España.

* First co-authors

Corresponding author: Neus Martínez-Abadías (neusmartinez@ub.edu)

ABSTRACT

Background

Approximately 30-40% of genetic and rare disorders manifest with distinct facial patterns. Traditionally, clinical geneticists have qualitatively assessed facial morphology to support preliminary diagnosis and guide confirmatory genetic testing. However, enhancing early diagnostic accuracy through facial biomarkers demands advanced 3D technologies for analyzing facial dysmorphologies, a deeper understanding of condition-specific disruptions in facial development, and a broader inclusion of diverse human populations.

To bridge this gap, we analyzed the 3D phenotypes associated with four genetic syndromes in an admixed Latin American population from Colombia. The sample comprised 47 individuals diagnosed with Down (DS), Morquio (MS), Noonan (NS), and Neurofibromatosis type 1 (NF1) syndromes along with 49 controls within the same age range. For each participant, we generated a 3D facial model using a multi-camera photogrammetric system and registered the 3D coordinates of 21 anatomical facial landmarks. Geometric morphometrics methods were employed to characterize syndrome-specific 3D facial dysmorphologies and to assess their variation compared to controls. We also examined whether these syndromes alter the ontogenetic trajectory of facial growth.

Results

Facial shape differed significantly in all syndromes except NF1. Consistently with previous 2D studies, we identified population-specific facial features in Colombian patients that are not reported in individuals of European descent. Pooled 3D analyses revealed a continuous spectrum of facial dysmorphology, with MS displaying the most distinct morphology and an altered ontogenic pattern. Facial size, sex and age were all

significant factors modulating facial shape, with diagnosis explaining 14% of variation in facial morphology.

Conclusions

Overall, these findings highlight the importance of accounting for interpopulation, sex and ontogenic variation in facial phenotypes to improve the diagnostic utility and of facial biomarkers. Such approaches may contribute to shortening the diagnostic odyssey for individuals with syndromic and rare genetic conditions.

KEYWORDS

Facial dysmorphology patterns; Down syndrome; Morquio syndrome; RASopathies; geometric morphometrics; interpopulation variation; ontogeny.

BACKGROUND

Genetic and rare diseases affect approximately 7% of the global population, corresponding to 500 million people worldwide (1,2). Although each rare disease occurs in a small number of individuals, fewer than 1 in 2,000 individuals, more than 7,000 distinct rare conditions have been identified, each characterized by unique clinical features (3). Early diagnosis is critical for effective genetic counseling, timely intervention, and prevention (4). However, significant diagnostic challenges persist due to limited understanding of underlying genetic mechanisms, overlapping clinical manifestations, and the scarcity of reliable diagnostic tools, particularly during early life (4). To overcome these challenges, researchers are exploring complementary strategies beyond traditional clinical and molecular diagnosis (5). Among these, facial dysmorphology analysis has emerged as a promising approach, combining the

analysis of facial imaging algorithms with genomic data to establish a link between patients' rare variants and potential facial gestalt (6,7).

Approximately 30-40% of rare genetic disorders exhibit distinct facial dysmorphology patterns, often resulting from disruptions in genetic signaling pathways that regulate craniofacial development, such as Sonic Hedgehog (SHH), Fibroblast Growth Factor (FGF), Bone Morphogenetic Protein (BMP), Wingless-related integration (Wnt), and Transforming Growth Factor β (TGF β) (8–15). These facial traits can range from subtle to severe (16), and previous research demonstrates that they provide valuable diagnostic cues (12–14).

Traditionally, facial assessment has relied on qualitative description and basic anthropometric measurements to guide preliminar diagnosis and confirmatory genetic testing (17–20). However, the variability and complexity of facial features both across and within syndromes demand highly trained specialists and remain challenging to evaluate (20). Recent advances in computer vision, machine learning, and geometric morphometrics now allow for more objective and automated facial analysis (12–14,21–27). Tools such as Face2Gene have shown significant potential and are increasingly integrated into clinical workflows (12–14). Nevertheless, current tools still face limitations in capturing the 3D complexity, evolution, and diversity of facial phenotypes (13,28).

First, most automated methods use two-dimensional (2D) images, which are easier to collect but fail to capture depth-related facial traits that are often altered in genetic disorders (12). In contrast, three-dimensional (3D) methods, though less accessible, can more effectively characterize disorder-specific facial patterns (13). Recent studies using 3D geometric morphometrics have revealed detailed phenotypic signatures in rare and genetic disorders, as well as differences between these patients and control individuals (13,27). Moreover, subtle yet significant shape differences have also been detected in patients with psychotic disorders (29).

Second, although facial dysmorphologies often emerge during embryonic development

and evolve throughout life (30), the influence of growth on facial shape in rare disorders

has been minimally explored. Understanding whether these conditions drive age-

related growth deviations is crucial for further adjusting diagnostic and prognostic

models (11).

And third, the limited availability of large-scale datasets for training diagnostic

algorithms has resulted in an overrepresentation of individuals of European descent

(13,31,32), leaving African, Asian, and Latin American populations underrepresented.

This imbalance is also evident in key medical references, such as Smith's

Recognizable Patterns of Human Malformation, which largely omits Latin American

individuals (16). Consequently, diagnostic algorithms based on European-centered

data fail to capture the full genetic and phenotypic diversity of other populations.

Increasing evidence suggests that incorporating diverse ancestries into biomedical

research enhances the identification of genetic variants associated to anthropometric

traits (33), craniofacial morphology (34) and disease susceptibility (35), ultimately

improving diagnostic accuracy.

3D facial shape variation across syndromes and ontogenesis in an admixed

population

Previously, we analyzed 2D facial dysmorphologies associated with genetic and rare

disorders in a highly admixed Colombian cohort of pediatric and adult individuals (7).

That study revealed population-specific traits and demonstrated that current diagnostic

algorithms based on 2D facial morphology performed less accurately in this cohort than

in European populations (7). Building on those findings, we now apply 3D analyses to

re-examine facial phenotypes of Down, Morquio, Noonan, and Neurofibromatosis type

1 syndromes within the same population.

Down syndrome (DS, OMIM 190685) is a genetic condition caused by trisomy of

chromosome 21 (36), occurring in approximately 1 in 800 births worldwide (37). This

chromosome imbalance leads to intellectual disability and multi-systemic

complications, including cardiovascular, respiratory, digestive, neurological, and

musculoskeletal issues (38). The craniofacial phenotype is characterized by

brachycephaly and midfacial flattening (39–41), along with oblique palpebral fissures,

hypertelorism, a broad nose with a depressed bridge, a small open mouth,

macroglossia, micrognathia, and a narrow palate, all of which can impair breathing,

feeding, and speech (38,40,41).

Morquio syndrome (MS, OMIM 253000), or mucopolysaccharidosis type IVA, is an

autosomal recessive disorder with a global birth prevalence of approximately 1 in

200,000-300,000 (42). Colombia reports one of the highest prevalence rates worldwide

(0.68 per 100,000 live births), likely due to founder effects (43,44). MS is caused by

mutations in *GALNS*, a gene encoding an enzyme required for glycosaminoglycan

metabolism (42). Clinical features include short stature, skeletal deformities, joint

hyperlaxity, and coarse facial features such as frontal bossing, flat nasal bridge, thick

lips, macroglossia, corneal opacity, glaucoma, and hypertelorism (42,45).

Noonan syndrome (NS, OMIM 163950) and Neurofibromatosis type 1 (NF1, OMIM

162200) are RASopathies (46), caused by alterations in the regulation of the RAS-

MAPK pathway (47). NS is an autosomal dominant condition (1 in 1,000-2,500 live

births) (47) caused by mutations in the *PTPN11* (50%), *SOS1* (23%), *RAF1* (5%), or

KRAS (<5%) genes (48). Clinical features include mild intellectual disability, cardiac

defects, skin pigmentation, and skeletal anomalies (49). Distinct facial traits include a

wide forehead, hypertelorism, ptosis, epicanthic folds, arched eyebrows, a broad neck,

low posterior hairline, and low-set posteriorly rotated ears (50,51).

NF1 is an autosomal dominant disorder associated with a prevalence of 1 in 4,000 live

births (52). It is caused by loss of function in *NF1*, a tumor suppressor gene regulating

RAS proteins (52). Clinical features include café-au-lait spots, axillary freckling, Lisch

nodules, optic gliomas, and skeletal anomalies (52,53). Craniofacial features include

macrocephaly, proptosis due to sphenoid wing agenesis or optic pathway gliomas,

maxillomandibular deformities, and dental anomalies (54).

Clinical manifestations associated with these genetic and rare disorders are known to

vary across population ancestry (7,55–57). The objective of this study is to quantify 3D

facial dysmorphologies associated with DS, MS, NS and NF1 in an admixed Colombian

population. Using 3D geometric morphometrics, we compared patients and control

individuals to define disorder-specific and ontogenetic facial patterns. We hypothesize

that the characterization of these features in an admixed population could improve

early, accurate, and unbiased diagnosis, supporting more personalized clinical

management.

METHODS

Population sample

The study sample, collected in 2021 in Cali, Colombia (7) comprised 96 individuals,

including children and adults (from 2 to 51 years) of both sexes (Table 1). Controls

were recruited at Universidad ICESI and Colegio Ecológico Scout; whereas individuals

diagnosed with Down, Morquio, Noonan and Neurofibromatosis type 1 syndromes

were recruited through the clinical genetics service at Hospital-Fundación Valle del Lili,

a tertiary referral center for genetic and rare disorders. Inclusion criteria for patients

required that clinical diagnoses were confirmed by molecular genetic testing. Clinical

history of craniofacial trauma and/or surgery were exclusion criteria for all participants.

Table 1: Cohort composition by diagnostic groups and sex.

Syndrome	Female	Male	Total
Down	11	8	19

Morquio	5	3	8
Noonan	5	3	8
Neurofibromatosis type 1	6	6	12
PATIENTS	27	20	47
CONTROL	34	15	49
TOTAL	61	35	**96**

The study was approved by the Ethics Committee for Human Research at Universidad

Icesi (approval record no. 309), the Bioethics Committee of the Universitat de

Barcelona (IRB03099-CER032514) and adhered to national and European research

guidelines, following the standards for medical research in humans recommended by

the Declaration of Helsinki. All participants provided written informed consents before

enrollment. For minors, parental or legal guardian consent was obtained for the collection

of facial photographs and clinical data.

Acquisition of Facial Images and Anatomical landmarks

Facial data were acquired via photogrammetry, a non-invasive, efficient, and cost-

effective technique for generating high-resolution 3D models (13,41). The setup

consisted of 10 synchronized digital cameras (SONY Alpha 58 +18-55) mounted on five

tripods at two heights, arranged in a semicircle one meter from the subject (41).

Cameras were triggered simultaneously via remote control to capture images of the

participants from multiple angles. People were asked to maintain an upright position

with a neutral facial expression. Overlapping images were processed in AgiSoft

PhotoScan to generate textured 3D surface meshes, which were scaled and saved as

Polygon File Format (PLY) files.

To analyze the facial morphology associated with DS, MS, NS and NF1, 21 anatomical

facial landmarks were manually placed on all individuals using 3DSlicer 5.0.2 (Figure 1;

Additional file 1) (58). A single trained observer conducted repeated measurements on

a subsample of 25 individuals (five per group) across five sessions at 48-hour intervals.

Intra-observer error was significantly lower than biological variation (p-value <0.010),

with a mean error <2 mm, within the accepted threshold for craniometric studies (59).

Landmark coordinates were subsequently used for morphometric analyses.

Figure 1. 3D facial reconstruction showing the 21 anatomical landmarks (numbered

symbols). Landmark definitions are provided in Additional file 1.

Quantitative Facial Shape Analyses

Facial shape differences were first evaluated within each syndrome, by comparing

patients and controls. Generalized Procrustes Analysis (GPA) was applied to the 3D

landmark coordinates (60), standardizing configuration through translation, scaling, and

rotation to achieve optimal superimposition (60). The resulting Procrustes coordinates

were analyzed via Principal Component Analysis (PCA). Morphological variation was

visualized in the morphospace defined by the first two principal components (PCs).

Given the limited sample size, analyses were performed without separating by sex to

preserve statistical power. Nevertheless, sex was visually distinguished in PCA plots

and incorporated as a covariate in subsequent analyses. Overlapping patient-control

groups indicated minimal dysmorphology, whereas distant clusters signified

pronounced phenotypic differences. Procrustes distances between the mean shape of

patient-control groups were calculated as the square root of the summed squared

differences between homologous landmarks (61). Statistical significance was assessed

via permutation tests (1,000 iterations).

Subsequently, GPA and PCA were performed on the pooled dataset to explore facial

shape differences across syndromes. A Procrustes ANOVA using the procD.lm function

in the geomorph R package, assessed the influence of diagnosis, size, age and sex on

shape variation (62–64).

Facial growth and ontogeny were examined through multivariate regressions of shape

on facial size and age (65). Facial size was quantified as centroid size, defined as the

square root of summed squared distances from landmarks to the centroid (65). When

size explained a statistically significant percentage of shape variation, Procrustes

distances were recalculated using the regression residuals of the multivariate

regression to remove the effect of allometry. Additionally, a Procrustes ANOVA

assessed the interaction between age and diagnosis for each syndrome. All

morphometric and statistical analyses were performed using MorphoJ (66) and

geomorph (62,63).

RESULTS

Distinct 3D morphological patterns in DS, MS and NS

The PCA revealed separation along PC1 between controls and individuals with all

syndromes (DS, MS, NS), except for NF1 (Figure 2). In DS (Figure 2A), facial changes

included a wider, flatter face; oblique palpebral fissures; hypertelorism; a depressed

nasal bridge; and a broad nose with widely spaced alae (Figure 2A). Mandibular

prognathism and thickened upper lips were also observed, with the latter emerging as

a distinct characteristic in this population. Procrustes distance analysis confirmed

significant shape differences between patients and controls (Procrustes distances=

0.0801; p <.0001).

Figure 2. Principal Component Analyses (PCA) results comparing controls with DS (A),

MS (B), NS (C), and NF1 (D). Female individuals indicated with empty symbols.

Morphings show frontal and lateral facial shape changes along PC1. When facial

shape differences between control and patients were significant (*) $p < .001$. Heatmaps

indicate regions of greatest variation. The faces in the figure are morphings which do

not belong to any real individual and are created from 3D landmark coordinates.

MS showed the most pronounced dysmorphology, with no overlap between patients

and controls (Figure 2B). It also displayed the largest Procrustes distance between

controls and patients (0.0943; p <.0001). Features included facial retrusion, increased

interorbital distance, nasal bridge, a protruding forehead, and a thickened upper lip

(Figure 2B).

NS presented milder differences, as indicated by a partial group overlap in PCA (Figure

2C) and the smallest Procrustes distance among affected groups (0.0683; p <.0001).

NS was associated with a longer, narrower face, mandibular retrognathism, and thick

lips. Neither mandibular retrognathism nor thick lips had been previously described in

other populations.

NF1 was the only syndrome that showed no significant shape differences. PCA

revealed complete overlap between patients and controls (Figure 2D), and Procrustes

distances were not statistically significant (0.0212; p=0.6719).

Continuous spectrum of facial dysmorphology

Analysis of the pooled sample (Figure 3) showed that the first two PCs accounted for

42.24% of total facial shape variation.

Figure 3. Principal Component Analysis (PCA) of pooled sample showing continuous variation in facial morphology across groups.

Although substantial overlap among groups was evident, positioning along PC1 reflected a gradient of dysmorphology. Control individuals clustered at the negative extreme, with NF1 cases largely overlapping and suggesting minimal dysmorphology associated with this rare disorder. NS individuals occupied an intermediate position, partially overlapping with both controls and NF1. In contrast, DS and MS cases were shifted toward the positive extreme, with DS showing the widest dispersion along PC1 and MS was the only syndrome that completely separated from controls (Figure 3).

Factors modulating facial morphology

First, we analyzed separately the effect of facial size. The multivariate regression of centroid size on facial shape confirmed a significant allometric effect (p <.0001), with facial size explaining 15.4% of shape variation. Procrustes distances between groups recalculated from the regression residuals confirmed that after removing the effect of

287   size, we still detected significant facial shape differences between controls and
288   individuals with DS, MS, and NS (Table 2).

290   **Table 2:** Procrustes distances and associated p-values based on regression residuals
291   of facial shape on centroid size among diagnoses. Significant facial differences
292   between groups are highlighted in bold.

	CONTROL	DS	MS	NS
DS	**0.046 (<.0001)**	-	-	-
MS	**0.0872 (<.0001)**	**0.0679 (<.0001)**	-	-
NS	**0.0452 (0.0023)**	**0.0648 (<.0001)**	**0.0772 (<.0001)**	-
NF1	0.0208 (0.6158)	**0.0392 (0.0291)**	**0.0815 (<.0001)**	**0.0449 (0.0084)**

Second, we performed a regression of facial shape on age to assess the effect of aging
pooling all syndromes. Results indicated a significant positive correlation, with age
explaining 9.7% of morphological variation (p <.0001). When analyzing each syndrome
separately, we detected that in DS, NS and NF1 the trajectory was parallel to controls
(Figure 4). The Procrustes ANOVA analyses showed that the interaction between age
and diagnosis was not statistically significant (DS: p=0.639; NS: p=0.635; NF1:
p=0.577), indicating a similar ontogenic development in these conditions as compared
to controls. Only MS displayed a divergent trajectory and altered postnatal
development (Figure 4B); however, the interaction factor did not reach significance
(p=0.074), likely due to the small sample size (Additional file 2).

Figure 4. Ontogenetic trajectories of facial shape comparing controls with DS (A), MS

(B), NS (C), and NF1 (D).

Finally, we assessed the simultaneous effect of all factors by performing a type II

Procrustes ANOVA (Table 3), which estimates the portion of variance in facial shape

that is attributable to each factor when the remaining covariates are adjusted for. All

four factors (diagnosis, age, size and sex) showed a significant influence on facial

shape, but diagnosis was the factor that explained most variance, 14% (Table 3).

Facial size, age and sex only explained 1-2% of facial shape variation when diagnosis

and the other factors had been accounted for.

Table 3. Procrustes ANOVA results showing the effects of diagnosis, centroid size, age,

and sex on facial shape variation. Reported values include degrees of freedom (Df),

317   sum of squares (SS), proportion of explained variance (R^2), F-statistics, and

318   permutation-based p-values.

	Df	SS	R^2	F	p-value
Diagnosis	4	0.1023	0.146	4.86	**<0.0001**
Centroid size	1	0.0179	0.026	3.40	**0.0005**
Age	1	0.0149	0.021	2.82	**0.0019**
Sex	1	0.0095	0.014	1.80	**0.0400**
Residuals	88	0.4634	0.660		

DISCUSSION

This study extends previous analyses of facial dysmorphologies associated with DS,

MS, NS, and NF1 in a Colombian population (7). The use of 3D geometric

morphometric methods represents a significant advancement over qualitative or 2D

quantitative approaches, providing a more precise and quantitative means of detecting

facial shape differences while controlling for confounding factors such as facial size

and age (11). Unlike 2D methods, 3D analyses incorporate depth, a critical shape

component for accurately capturing syndrome-specific dysmorphologies and thus

enhance the potential application of facial biomarkers for diagnosis and prognosis of

genetic and rare disorders (12–14,21–27).

Our findings indicate that, although Colombian individuals share general

dysmorphological patterns reported in other populations, they also display population-

specific traits, reflecting the diverse genetic ancestry of this Latin-American population

(7). In Cali, admixture with the indigenous Amerindian population began in the sixteenth

century with the arrival of Spanish colonizers (67). In the eighteenth century, the

establishment of large colonial settlements of African slaves for sugar cane exploitation

significantly changed the population structure of Valle del Cauca (67). Currently, the

Amerindian and African ancestry predominate in this Colombian region over European

ancestry (68).

For DS, observed features largely align with reports from European-descent

populations (36,38,39,41), but a thicker upper lip relative to the lower lip emerges as a

distinct characteristic in this Latin American population. In MS, all traits described by

Suárez-Guerrero et al. (2020) were present, including the same lip thickness difference

noted in DS. Our findings for NS diverged from European-based descriptions (50), with

Colombian individuals showing mandibular retrognathism and thick lips, which are

features not consistently reported elsewhere. For NF1, no significant differences were

detected, consistent with prior studies (54), indicating subtle, non-significant facial

variation in this syndrome.   Although previous research suggested shared

dysmorphologies among RASopathies (46), our results support the differentiation of NS

and NF1 based on facial phenotypes.

Pooling all syndromic groups revealed a continuous spectrum of facial variation: NS

showed mild to moderate changes, DS moderate to severe, and MS the most severe

dysmorphologies. These findings expand upon earlier 2D analyses (7), revealing

additional 3D shape details and allometric effects. 3D analyses allowed for the

identification of depth-related traits, such as mandibular prognathism or retrognathism,

while enabling the visualization of syndrome-specific facial morphology through 3D

morphs. The observed variation in explanatory power across variables reflects shared

variance and interaction effects, emphasizing the need for multifactorial modeling.

Analysis of ontogenetic trajectories showed that NS, NF1 and DS followed similar

growth patterns to controls. In contrast, MS exhibited deviations, suggesting altered

postnatal facial development. This result is consistent with previous evidence

describing that, in mucopolysaccharidosis syndromes, facial dysmorphologies of MS

are cumulative and increase over lifetime due to progressive lysosomal accumulation

of glycosaminoglycans (GAGs) (42). However, statistical significance was not reached

when evaluating the interaction between age and diagnosis, likely due to the small

sample size. Overall, these results underscore the need to specifically assess

ontogeny to improve the prognosis and clinical management of individuals with genetic
and rare disorders.

Research on rare conditions is often constrained by their low prevalence, making it
crucial to expand both sample size and diversity (7,13). Broader representation across
different ages, sexes, and populations from around the world would provide a more
comprehensive understanding of phenotypic variability. Larger datasets would support
more refined analyses of facial phenotypes, the identification of morphological
differences based on facial distances, and the early recognition of dysmorphologies
during childhood development.

Increasing diversity in biomedical research would not only enhance current diagnostic
models but also improve the identification and mapping of genetic variants associated
with anthropometric traits and diseases (69). Incorporating ancestral diversity into
biomedical studies would enable the establishment of more precise and specific
biological profiles for each syndrome, considering the impact of ancestry on facial
phenotype (15). Moroever, integrating genetic data with phenotypic analyses could
enable the identification of genotype-phenotype correlations, which are critical for a
deeper understanding of molecular pathways and phenotypic subgroups associated
with genetic disorders, improving genetic variant interpretation, ultimately supporting
precise diagnosis and personalized care (70).

In the future, translating facial biomakers into clinical practice will require the
development and validation of low-cost 3D facial shape acquisition methodologies (71).
Such tools have the potential to considerably shorten the diagnostic odyssey for rare
diseases, particularly in regions where access to genetic testing remains limited.

CONCLUSION

Overall, our 3D morphometric analyses confirmed distinct diagnostic patterns in DS,

MS and NS. This finding highlights the potential of facial shape analysis to aid the

diagnosis of these genetic conditions, and the importance to incorporate ontogenetic

and interpopulation variation to optimize their clinical applicability across diverse

human populations. In regions with limited access to genetic testing, these

morphometric approaches could offer a non-invasive, affordable, and accessible

alternative to support early diagnosis and clinical decision-making.

LIST OF ABBREVIATIONS

3D: Three dimensional

DS: Down syndrome

MS: Morquio syndrome

NS: Noonan syndrome

NF1: Neurofibromatosis type 1

2D: Two dimensional

SHH: Sonic Hedgehog

FGF: Fibroblast Growth Factor

BMP: Bone Morphogenetic Protein

TGF β: Transforming Growth Factor β

GPA: Generalized Procrustes Analysis

PCA: Principal Components Analysis

PCs: Principal Components

DECLARATIONS

- **Ethics approval and consent to participate**

The study was approved by the Ethics Committee for Human Research at Universidad Icesi (approval record no. 309), the Bioethics Committee of the Universitat de Barcelona (IRB03099-CER032514) and adhered to national guidelines and protocols, following the standards for medical research in humans recommended by the Declaration of Helsinki. All participants provided informed consent before enrollment. For minors, consent was obtained from parents or legal guardians for the acquisition of facial photographs and associated clinical data.

- **Consent for publication**

The faces used in this manuscript for illustrative purposes do not belong to any real individual and correspond to virtual models created from random facial meshes morphed by 3D landmark coordinates defining axes of morphological variation. Therefore, no consent for publication is required.

- **Availability of data and materials**

Raw image data cannot be made available due to restrictions imposed by ethics approval. Landmark data supporting the findings of this study are available from the corresponding author upon reasonable request.

- **Competing interests**

The authors declare that they have no competing interests.

- **Funding**

This study was funded by Proyecto COL0012168-1097 Interfacultades-ICESI, Beca predoctoral Fundación Álvaro Entrecanales-Lejeune to LME-Q, the Agencia Española de Investigación (projects PID2023-147001OB-C21/C22 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU), Programa de

Contractació d'Investigadors Predoctorals en Formació de la Universitat de

Barcelona (PREDOCS-UB 2024), Wenner Gren Foundation for Anthropological

Research (Gr. 10657), Agència de Gestió d'Ajuts Universitaris i de Recerca

(AGAUR) of the Generalitat de Catalunya (2021 SGR00706 and 2021

SGR01396), and Biological Anthropological Master UB-UAB.

- **Author's contributions**

MAM, MP, EE, AC, HP and NMA conceived the project. LMEQ, EC, EG, ORR,

MRT and HP recruited participants, performed 3D facial scanning and

diagnosed cases. MAM, MP, AHL, XS, AC and NMA performed the

morphometric analyses and interpreted results. MAM, MP, and NMA prepared

the manuscript and figures. All authors critically reviewed the manuscript.

Acknowledgements

We are grateful for the voluntary collaboration of all participants, including

children and their families. We are thankful to Colegio Ecológico Scout and

Universidad Icesi for granting us permission to organize the photographic

sessions in Colombia.

REFERENCES

460
461 1. Baird PA, Anderson TW, Newcombe HB, Lowry RB. Genetic disorders in children and young adults: a population study. Am J Hum Genet. 1988 May;42(5):677–93.

462
463
464 2. Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020 Feb;28(2):165–73.

465
466 3. Health TLG. The landscape for rare diseases in 2024. Lancet Glob Health. 2024 Mar 1;12(3):e341.

467
4. Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. The Lancet. 2008 June 14;371(9629):2039–41.

5. Gülbakan B, Özgül RK, Yüzbaşıoğlu A, Kohl M, Deigner HP, Özgüç M. Discovery of
biomarkers in rare diseases: innovative approaches by predictive and personalized
medicine. EPMA J. 2016;7(1):24.

6. Jansen S, Vissers LELM, de Vries BBA. The Genetics of Intellectual Disability.
Brain Sci. 2023 Jan 30;13(2):231.

7. Echeverry-Quiceno LM, Candelo E, Gómez E, Solís P, Ramírez D, Ortiz D, et al.
Population-specific facial traits and diagnosis accuracy of genetic and rare
diseases in an admixed Colombian population. Sci Rep. 2023 Apr 27;13(1):6869.

8. Francis-West P, Ladher R, Barlow A, Graveson A. Signalling interactions during
facial development. Mech Dev. 1998 July;75(1–2):3–28.

9. Martínez-Abadías N, Heuzé Y, Wang Y, Jabs EW, Aldridge K, Richtsmeier JT.
FGF/FGFR Signaling Coordinates Skull Development by Modulating Magnitude of
Morphological Integration: Evidence from Apert Syndrome Mouse Models. PLOS
ONE. 2011 Oct 28;6(10):e26425.

10. Richtsmeier JT, Flaherty K. Hand in glove: brain and skull in development and
dysmorphogenesis. Acta Neuropathol (Berl). 2013 Apr;125(4):469–89.

11. Hallgrimsson B, Percival CJ, Green R, Young NM, Mio W, Marcucio R.
Morphometrics, 3D Imaging, and Craniofacial Development. Curr Top Dev Biol.
2015;115:561–97.

12. Gurovich Y, Hanani Y, Bar O, Nadav G, Fleischer N, Gelbman D, et al. Identifying
facial phenotypes of genetic disorders using deep learning. Nat Med. 2019
Jan;25(1):60–4.

13. Hallgrímsson B, Aponte JD, Katz DC, Bannister JJ, Riccardi SL, Mahasuwan N, et
al. Automated syndrome diagnosis by three-dimensional facial imaging. Genet
Med. 2020;22(10):1682–93.

14. Hsieh TC, Bar-Haim A, Moosa S, Ehmke N, Gripp KW, Pantel JT, et al.
GestaltMatcher: Overcoming the limits of rare disease matching using facial
phenotypic descriptors. Nat Genet. 2022 Mar;54(3):349–57.

15. Naqvi S, Hoskens H, Wilke F, Weinberg SM, Shaffer JR, Walsh S, et al. Decoding
the Human Face: Progress and Challenges in Understanding the Genetics of
Craniofacial Morphology. Annu Rev Genomics Hum Genet. 2022 Aug 31;23:383–
412.

16. Smith's Recognizable Patterns of Human Malformation [Internet]. 2013 [cited 2025
Dec 1]. Available from: https://shop.elsevier.com/books/smiths-recognizable-
patterns-of-human-malformation/jones/978-1-4557-3811-3

17. Kolar JC, Munro IR, Farkas LG. Anthropometric evaluation of dysmorphology in
craniofacial anomalies: Treacher Collins syndrome. Am J Phys Anthropol. 1987
Dec;74(4):441–51.

18. Aase JM. Diagnostic Dysmorphology. Springer; 1990. 321 p.

19. Merks JHM, van Karnebeek CDM, Caron HN, Hennekam RCM. Phenotypic
abnormalities: terminology and classification. Am J Med Genet A. 2003 Dec
15;123A(3):211–30.

20. Reardon W, Donnai D. Dysmorphology demystified. Arch Dis Child Fetal Neonatal
Ed. 2007 May;92(3):F225–9.

21. Hammond P, Hutton TJ, Allanson JE, Campbell LE, Hennekam RCM, Holden S, et
al. 3D analysis of facial morphology. Am J Med Genet A. 2004;126A(4):339–48.

22. Hammond P. The use of 3D face shape modelling in dysmorphology. Arch Dis
Child. 2007 Dec;92(12):1120–6.

23. Hammond P, Suttie M. Large-scale objective phenotyping of 3D facial morphology.
Hum Mutat. 2012 May;33(5):817–25.

24. Hurst ACE. Facial recognition software in clinical dysmorphology. Curr Opin
Pediatr. 2018 Dec;30(6):701–6.

25. Köhler S, Carmody L, Vasilevsky N, Jacobsen JOB, Danis D, Gourdine JP, et al.
Expansion of the Human Phenotype Ontology (HPO) knowledge base and
resources. Nucleic Acids Res. 2019 Jan 8;47(D1):D1018–27.

26. Bannister JJ, Crites SR, Aponte JD, Katz DC, Wilms M, Klein OD, et al. Fully
Automatic Landmarking of Syndromic 3D Facial Surface Scans Using 2D Images.
Sensors. 2020 June 3;20(11):3171.

27. Aponte JD, Bannister JJ, Hoskens H, Matthews H, Katsura K, Da Silva C, et al. An
interactive atlas of three-dimensional syndromic facial morphology. Am J Hum
Genet. 2024 Jan 4;111(1):39–47.

28. Echeverry-Quiceno LM, Llambrich S, Heredia-Lidón Á, Giménez S, Rozalem-
Aranha M, Inampudi P, et al. Potential of facial biomarkers for Alzheimer's disease
and obstructive sleep apnea in Down syndrome and general population. FASEB J
Off Publ Fed Am Soc Exp Biol. 2025 Mar 31;39(6):e70480.

29. Hostalet N, González A, Salgado-Pineda P, Gonzàlez-Colom R, Canales-
Rodríguez EJ, Aguirre C, et al. Face-brain correlates as potential sex-specific
biomarkers for schizophrenia and bipolar disorder. Psychiatry Res. 2024
Sept;339:116027.

30. Viteri J, Carrasco AM, Jácome M, Vaca G, Tubón I, Rodríguez V, et al.
Enfermedades Huérfanas Orphaned Diseases. Arch Venez Farmacol Ter.
2020;39(5):627–36.

31. Allanson JE, Cunniff C, Hoyme HE, McGaughran J, Muenke M, Neri G. Elements
of Morphology: Standard Terminology for the Head and Face. Am J Med Genet A.
2009 Jan;149A(1):6–28.

32. Masnada S, Gibelli D, Dolci C, De Giorgis V, Cappella A, Veggiotti P, et al. 3D facial
morphometry in Italian patients affected by Aicardi syndrome. Am J Med Genet A.
2020 Oct;182(10):2325–32.

33. Fernández-Rhodes L, Graff M, Buchanan VL, Justice AE, Highland HM, Guo X, et
al. Ancestral diversity improves discovery and fine-mapping of genetic loci for
anthropometric traits-The Hispanic/Latino Anthropometry Consortium. HGG Adv.
2022 Apr 14;3(2):100099.

34. Goovaerts S, Hoskens H, Eller RJ, Herrick N, Musolf AM, Justice CM, et al. Joint
multi-ancestry and admixed GWAS reveals the complex genetics behind human
cranial vault shape. Nat Commun. 2023 Nov 16;14(1):7436.

35. Wojcik GL, Graff M, Nishimura KK, Tao R, Haessler J, Gignoux CR, et al. Genetic
analyses of diverse populations improves discovery for complex traits. Nature.
2019 June;570(7762):514–8.

36. Antonarakis SE, Skotko BG, Rafii MS, Strydom A, Pape SE, Bianchi DW, et al.
Down syndrome. Nat Rev Dis Primer. 2020 Feb 6;6(1):9.

37. Roper RJ, Reeves RH. Understanding the basis for Down syndrome phenotypes.
PLoS Genet. 2006 Mar;2(3):e50.

38. Bull MJ. Down Syndrome. N Engl J Med. 2020 June 11;382(24):2344–52.

39. Starbuck JM, Cole TM, Reeves RH, Richtsmeier JT. Trisomy 21 and facial
developmental instability. Am J Phys Anthropol. 2013 May;151(1):49–57.

40. Vicente A, Bravo-González LA, López-Romero A, Muñoz CS, Sánchez-Meca J.
Craniofacial morphology in down syndrome: a systematic review and meta-
analysis. Sci Rep. 2020 Nov 16;10(1):19895.

41. Starbuck JM, Llambrich S, Gonzàlez R, Albaigès J, Sarlé A, Wouters J, et al. Green
tea extracts containing epigallocatechin-3-gallate modulate facial development in
Down syndrome. Sci Rep. 2021 Feb 25;11(1):4715.

42. Suarez-Guerrero JL, Gómez Higuera PJI, Arias Flórez JS, Contreras-García GA.
Mucopolisacaridosis: características clínicas, diagnóstico y de manejo. Rev Chil
Pediatría. 2016 July 1;87(4):295–304.

43. Pachajoa H, Acosta MA, Alméciga-Díaz CJ, Ariza Y, Diaz-Ordoñez L, Caicedo-
Herrera G, et al. Molecular characterization of mucopolysaccharidosis type IVA
patients in the Andean region of Colombia. Am J Med Genet C Semin Med Genet.
2021 Sept;187(3):388–95.

44. Uribe A, Giugliani R. Selective screening for lysosomal storage diseases with dried
blood spots collected on filter paper in 4,700 high-risk colombian subjects. JIMD
Rep. 2013;11:107–16.

45. Suárez Obando F, Zarante Montoya I. Aspectos clínicos y manejo integral del
síndrome de Morquio. Univ Médica Vol 48 Núm 2 2007 [Internet]. 2023 Aug 24
[cited   2025   Dec   1];   Available   from:
http://repositorioslatinoamericanos.uchile.cl/handle/2250/8419234

46. Zenker M. Clinical overview on RASopathies. Am J Med Genet C Semin Med
Genet. 2022;190(4):414–24.

47. Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet Lond
Engl. 2013 Jan 26;381(9863):333–42.

48. Rauen KA. Cardiofaciocutaneous Syndrome. In: Adam MP, Bick S, Mirzaa GM,
Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle
(WA): University of Washington, Seattle; 1993 [cited 2025 Dec 1]. Available from:
http://www.ncbi.nlm.nih.gov/books/NBK1186/

49. Lee BH, Yoo HW. Noonan syndrome and RASopathies: Clinical features, diagnosis
and management. J Genet Med. 2019;16(1):1–9.

50. Hernández-Martín A, Torrelo A. Rasopatías: trastornos del desarrollo con
predisposición al cáncer y manifestaciones cutáneas. Actas Dermo-Sifiliográficas.
2011 July 1;102(6):402–16.

51. Cremers CW, van der Burgt CJ. Hearing loss in Noonan syndrome. Int J Pediatr
Otorhinolaryngol. 1992 Jan;23(1):81–4.

52. Pasmant E, Vidaud M, Vidaud D, Wolkenstein P. Neurofibromatosis type 1: from
genotype to phenotype. J Med Genet. 2012 Aug;49(8):483–9.

53. Cimino PJ, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol.
2018;148:799–811.

54. Chauvel-Picard J, Lion-Francois L, Beuriat PA, Paulus C, Szathmari A, Mottolese
C, et al. Craniofacial bone alterations in patients with neurofibromatosis type 1.
Childs Nerv Syst ChNS Off J Int Soc Pediatr Neurosurg. 2020 Oct;36(10):2391–9.

55. Kruszka P, Addissie YA, McGinn DE, Porras AR, Biggs E, Share M, et al. 22q11.2
deletion syndrome in diverse populations. Am J Med Genet A. 2017
Apr;173(4):879–88.

56. Kruszka P, Porras AR, Addissie YA, Moresco A, Medrano S, Mok GTK, et al.
Noonan syndrome in diverse populations. Am J Med Genet A. 2017
Sept;173(9):2323–34.

57. Kruszka P, Porras AR, Sobering AK, Ikolo FA, La Qua S, Shotelersuk V, et al. Down
syndrome in diverse populations. Am J Med Genet A. 2017 Jan;173(1):42–53.

58. Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin JC, Pujol S, et al.
3D Slicer as an image computing platform for the Quantitative Imaging Network.
Magn Reson Imaging. 2012 Nov;30(9):1323–41.

59. Stull KE, Tise ML, Ali Z, Fowler DR. Accuracy and reliability of measurements
obtained from computed tomography 3D volume rendered images. Forensic Sci Int.
2014 May;238:133–40.

60. Dryden IL. Shape Analysis. In: Wiley StatsRef: Statistics Reference Online
[Internet]. John Wiley & Sons, Ltd; 2014 [cited 2025 Dec 1]. Available from:
https://onlinelibrary.wiley.com/doi/abs/10.1002/9781118445112.stat05087

61. Klingenberg CP. Size, shape, and form: concepts of allometry in geometric
morphometrics. Dev Genes Evol. 2016 June 1;226(3):113–37.

62. Adams D, Collyer M, Kaliontzopoulou A, Baken E. geomorph: Geometric
Morphometric Analyses of 2D and 3D Landmark Data [Internet]. 2025 [cited 2025
Dec   1].   Available   from: https://cran.r-
project.org/web/packages/geomorph/index.html

63. Baken EK, Collyer ML, Kaliontzopoulou A, Adams DC. geomorph v4.0 and
gmShiny: Enhanced analytics and a new graphical interface for a comprehensive
morphometric experience. Methods Ecol Evol. 2021 Dec;12(12):2355–63.

632 64. Adams DC, Otárola-Castillo E. geomorph: an r package for the collection and
633   analysis of geometric morphometric shape data. Methods Ecol Evol. 2013;4(4):393.

634 65. Mitteroecker P, Gunz P. Advances in Geometric Morphometrics. Evol Biol. 2009
635   June 1;36(2):235–47.

636 66. Klingenberg CP. MorphoJ: an integrated software package for geometric
637   morphometrics. Mol Ecol Resour. 2011 Mar;11(2):353–7.

638 67. Urrea-Giraldo F, Candelo Álvarez AF. Cali, an enlarged region city: an
639   approximation from the ethnic-racial dimension and population flows. Soc Econ.
640   2017 July;(33):145–74.

641 68. Adhikari K, Chacón-Duque JC, Mendoza-Revilla J, Fuentes-Guajardo M, Ruiz-
642   Linares A. The Genetic Diversity of the Americas. Annu Rev Genomics Hum Genet.
643   2017 Aug 31;18:277–96.

644 69. Fernández-Rhodes L, Graff M, Buchanan VL, Justice AE, Highland HM, Guo X, et
645   al. Ancestral diversity improves discovery and fine-mapping of genetic loci for
646   anthropometric traits—The Hispanic/Latino Anthropometry Consortium. Hum Genet
647   Genomics Adv. 2022 Mar 11;3(2):100099.

648 70. Dingemans AJM, Hinne M, Truijen KMG, Goltstein L, van Reeuwijk J, de Leeuw N,
649   et al. PhenoScore quantifies phenotypic variation for rare genetic diseases by
650   combining facial analysis with other clinical features using a machine-learning
651   framework. Nat Genet. 2023 Sept;55(9):1598–607.

652 71. Heredia-Lidón Á, Moñux-Bernal A, González A, Echeverry-Quiceno LM, Andreu-
653   Montoriol M, et
654   al. A Geometric and Morphometric Methodology for Evaluating Low-Cost  3D
655   Facial Acquisition and Reconstruction Techniques. In: Gonçalves, N., Oliveira, H.P.,
656   Sánchez,                    J.A.
657   (eds) Pattern Recognition and Image Analysis. IbPRIA 2025. Lecture Notes in
658   Computer Science, vol 15937:163-174.

659